Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31196854.
- Also identified by DOI 10.1158/1078-0432.CCR-19-1481 and PMC identifier 6697558.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery of novel targets, like Aurora Kinase A, may provide new avenues of single-agent and combinatorial therapy for myelofibrosis and restoration of normal bone marrow function.<i>See related article by Gangat et al., p. 4898</i>.
Medical subject headings
- Janus Kinase Inhibitors
- Primary Myelofibrosis